Aclaris Therapeutics' ATI-2138 Shows Strong Phase 2a Efficacy in Atopic Dermatitis, Reducing EASI by 77%
Summary
Aclaris Therapeutics announced additional positive Phase 2a trial results for its investigational drug ATI-2138 in moderate-to-severe Atopic Dermatitis, presented at the 2026 AAD Annual Meeting. The data showed significant improvements, including a 77% reduction in Eczema Area and Severity Index (EASI) and a 70% improvement in Body Surface Area (BSA) at week 12, along with better itch and quality of life scores. For a clinical-stage biopharmaceutical company, these strong, detailed efficacy results for a key pipeline asset are a material de-risking event, validating the drug's therapeutic potential and mechanism of action. This positive data could significantly boost investor confidence and the drug's commercial prospects, with future focus on progression to later-stage trials.
At the time of this announcement, ACRS was trading at $3.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.1M. The 52-week trading range was $1.05 to $4.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.